EXEL outlines growth priorities across RCC, NETs and upcoming launches
EXEL says it plans to expand product franchises in RCC and NETs. It cites CABOMETYX steady market share gains and highlights zanzalintinib launch timing in CRC and NETs, supported by AI-driven efficiency and capital allocation discipline.